Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB5121 in CNS Lymphoma
NCT05242146Phase 1Terminated
- Sponsor
- Gossamer Bio
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of GB5121 in primary central nervous system lymphoma (PCNSL), primary vitreoretinal lymphoma (PVRL) and secondary central nervous system lymphoma (SCNSL), sponsored by Gossamer Bio. Primary endpoints: Incidence of Adverse Events, Dose Limiting Toxicity(ies) and 3 more. Started May 2022; status: terminated.
02
Drugs
GB5121
03
Conditions
primary central nervous system lymphoma (PCNSL)primary vitreoretinal lymphoma (PVRL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT05242146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242146.